The Role of Vaspin in the Development of Metabolic and Glucose Tolerance Disorders and Atherosclerosis

Abstract EN

In recent years, most research efforts have been focused on studying insulin-sensitizing adipokines.

One of the most recently discovered adipokines is vaspin, a visceral adipose tissue-derived serine protease inhibitor.

Vaspin levels have been found significantly increased in mice with obesity and insulin resistance.

It has been assumed that vaspin serves as an insulin sensitizer with anti-inflammatory effects and might act as a compensatory mechanism in response to decreased insulin sensitivity.

Most studies in humans have shown a positive correlation between vaspin gene expression and serum levels, and metabolic syndrome parameters.

Vaspin gene expression is influenced by age and gender, and the administration of insulin sensitizers enhances it in mice, whereas the use of metformin decreases serum vaspin levels in humans, probably due to different regulatory mechanisms.

Presumably vaspin plays local and endocrine role in the development of initial and advanced atherosclerosis in obese subjects and might be used as a predictor of coronary and cerebrovascular disease.

It is believed that vaspin could be regarded as a new link between obesity and related metabolic disorders, including glucose intolerance.

The entire understanding of vaspin intimate mechanism of action might enable the development of novel etiology-based treatment strategies, targeting metabolic and glucose tolerance disorders.